Hydroxocobalamin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Hydroxocobalamin
- Hydroxocobalamin: From Vitamin B12 Deficiency / Cyanide Poisoning to Esophageal Varices without Bleeding
Hydroxocobalamin: From Vitamin B12 Deficiency / Cyanide Poisoning to Esophageal Varices without Bleeding
One-Sentence Summary
Hydroxocobalamin is clinically known for treating vitamin B12 deficiency and as an antidote for cyanide poisoning, though this specific approved-indication data was not captured in the current evidence pack. The TxGNN model predicts it may be effective for Esophageal Varices (without bleeding) — and, at an identical score, for esophageal varices with bleeding — but currently zero clinical trials and zero publications support either direction, and no plausible pharmacological mechanism has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin B12 deficiency; cyanide poisoning antidote (from known drug class information — not confirmed via a Finnish regulatory source in this evidence pack) |
| Predicted New Indication | Esophageal Varices without Bleeding (a second, identically-scored prediction exists for esophageal varices with bleeding) |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for hydroxocobalamin in this evidence pack (flagged as a High-severity data gap). Based on known clinical use, hydroxocobalamin acts as a vitamin B12 precursor for deficiency replacement and, at high doses, as a cyanide antidote (it binds cyanide ions to form cyanocobalamin, which is renally excreted).
Neither of these established mechanisms offers a pharmacological rationale for a role in esophageal varices, which are a manifestation of portal hypertension typically managed with agents that modulate splanchnic blood flow or portal pressure (e.g., octreotide, terlipressin, vasopressin, non-selective beta-blockers). There is no known hemodynamic, vasoactive, or vascular-remodeling effect of hydroxocobalamin that would connect it to this indication.
Given this, the TxGNN score of 99.23% should be interpreted strictly as a knowledge-graph correlation, not as evidence of biological plausibility. With no clinical trials, no literature, and no identifiable mechanistic link, this prediction currently lacks a testable scientific hypothesis and sits at the lowest confidence tier (L5).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Hydroxocobalamin is not currently marketed in Finland (0 authorizations on record), so no product/authorization table is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a raw TxGNN model score, with no clinical trials, no literature, and no identifiable mechanistic rationale connecting hydroxocobalamin to esophageal varices. This is an L5 / S0 candidate and does not meet the bar to advance to safety or clinical evaluation.
To proceed, the following is needed:
- TFDA/Fimea package insert warnings and contraindications (currently blocking — safety profile cannot be assessed)
- Confirmed mechanism of action (DrugBank query)
- A plausible biological hypothesis linking hydroxocobalamin to portal hypertension/variceal pathophysiology before further evidence search is warranted
- Ongoing monitoring for any new trials or literature on this drug-disease pair
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.